Valuation : Cytosorbents Corporation

Market Cap 21.09M 18.17M 17.04M 15.55M 29.3M 2.02B 29.4M 202M 78.87M 1.02B 79.18M 77.46M 3.37B P/E 2026 *
-1.53x
P/E 2027 * -7.46x
Enterprise Value 21.09M 18.17M 17.04M 15.55M 29.3M 2.02B 29.4M 202M 78.87M 1.02B 79.18M 77.46M 3.37B EV / Sales 2026 *
0.54x
EV / Sales 2027 * 0.48x
Free-Float
84.28%
Yield 2026 *
-
Yield 2027 * -
1 day-1.41%
1 week-9.30%
Current month-7.01%
1 month-9.30%
3 months-32.31%
6 months-55.40%
Current year-47.50%
1 week 0.32
Extreme 0.32
0.39
1 month 0.3
Extreme 0.3
0.4
Current year 0.3
Extreme 0.3
0.84
1 year 0.3
Extreme 0.3
1.04
3 years 0.3
Extreme 0.3
2.66
5 years 0.3
Extreme 0.3
9.8
10 years 0.3
Extreme 0.3
14.95
Manager TitleAgeSince
Chief Executive Officer 55 2008-07-23
President 68 2020-04-27
Director of Finance/CFO 62 2024-08-13
Director TitleAgeSince
Chairman 62 -
Director/Board Member 55 2008-12-31
Director/Board Member 77 2011-07-24
Date Insider Type Main position Quantity % Market Cap.
11/18/25 Free

Chief Executive Officer

100,000 0.1593%
8/8/25 Free

Chief Financial Officer

161,500 0.2579%
8/8/25 Free

Chief Executive Officer

242,000 0.3865%
Change 5-day change 1-year change 3-year change Capi.($)
-1.41%-9.30%-64.13%-86.47% 21.09M
-1.35%-1.13%+27.04%+14.12% 230B
+0.18%-1.27%+5.25%-17.37% 152B
+1.51%-1.64%-21.37%+23.59% 132B
+0.36%-7.01%-55.71%-12.92% 67.88B
+0.29%+0.47%+11.06%+18.65% 52B
+0.66%-1.69%-16.57%-13.62% 51.05B
-2.44%-3.25%+23.11%+28.29% 43.38B
-1.56%+0.97%+39.32%+47.34% 40.74B
-5.31%-1.74%+117.39%+36.28% 32.55B
Average -0.93%-2.18%+6.54%+3.79% 80.12B
Weighted average by Cap. -0.46%-1.50%+8.21%+9.30%

Financials

2026 *2027 *
Net sales 38.88M 33.5M 31.41M 28.68M 54.02M 3.72B 54.19M 373M 145M 1.88B 146M 143M 6.22B 44.16M 38.05M 35.68M 32.57M 61.36M 4.22B 61.55M 423M 165M 2.13B 166M 162M 7.06B
Net income -13.91M -11.99M -11.24M -10.26M -19.33M -1.33B -19.39M -133M -52.02M -671M -52.23M -51.09M -2.23B -2.77M -2.39M -2.24M -2.04M -3.85M -265M -3.86M -26.57M -10.37M -134M -10.41M -10.18M -443M
Net Debt - -
Logo Cytosorbents Corporation
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Employees
129
Date Price Change Volume
26-08-28 $0.3356 -1.41% 113,684
26-08-27 $0.3404 -5.44% 108,592
26-08-26 $0.3600 +1.32% 26,283
26-08-25 $0.3553 -4.02% 123,629
26-08-24 $0.3702 +0.05% 158,191
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.3356USD
Average target price
2.375USD
Spread / Average Target
+607.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CTSO Stock